<DOC>
	<DOCNO>NCT02360111</DOCNO>
	<brief_summary>This pilot study do small number patient . The purpose study test safety benefit give type chemotherapy - cyclophosphamide - transplant prevent graft versus host disease ( GVHD ) patient abnormal kidney function . GVHD one common complication stem cell transplant .</brief_summary>
	<brief_title>GVHD Prophylaxis With Post Transplant Cyclophosphamide Patients With Renal Insufficiency Undergoing Conventional 8/8 HLA-matched Related Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Age : Patients age 18 deem eligible transplant treat physician . Disease status : 1 . AML â‰¥ 1st remission exclude 1st remission 'good risk ' cytogenetic feature ( i.e . ( 8 ; 21 ) , ( 15 ; 17 ) , inv 16 ) . 2 . Secondary AML 3 . ALL/LL 1st remission clinical molecular feature indicate high risk relapse ; ALL &gt; 2nd remission 4 . CML fail respond , progress tolerate appropriate TKI therapy first chronic phase disease ; CML accelerate phase , second chronic phase , CR accelerate phase blast crisis . 5 . NonHodgkins lymphoma chemoresponsive disease follow category : 1. high grade lymphoma fail achieve first CR relapse follow 1st remission candidate autologous transplant transplant require use calcineurin inhibitor . 2. NHL therapy responsive disease consider curable outside transplant set eligible/appropriate autologous transplant high priority protocol . 6 . Myelodysplastic syndrome ( MDS ) : RA/RCMD high risk cytogenetic feature transfusion dependence , RAEB1 RAEB2 AML evolve MDS , eligible high priority protocol . 7 . Chronic myelomonocytic leukemia : CMML1 CMML2 , advance polycythemia vera , myelofibrosis . 1 . Patients must healthy HLA compatible ( 8/8 molecularly match relate , unrelated ) donor willing undergo BM harvest PBSC apheresis GCSF administration . BM prefer graft source . 2 . Patients diagnose form acute leukemia must receive induction least one course consolidation chemotherapy pretransplant Patients must Karnofsky Performance Status &gt; 70 % Patients eGFR &lt; 60 ml/min/1.73 m2 1 . Patients must adequate organ function measure : Cardiac : asymptomatic symptomatic LVEF rest must &gt; 50 % must improve exercise . 2 . Hepatic : ALT &lt; 3 x ULN total serum bilirubin &lt; 1.5 x ULN , unless congenital benign hyperbilirubinemia 3 . Renal : eGFR &gt; 30 ml/min/1.73 m2 4 . Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Patient must fully match related unrelated donor willing donate stem cell . Major surgery irradiation within two week . Active CNS extramedullary malignant disease . Active uncontrolled infection time transplantation include active infection Aspergillus mold , HIV infection Pregnant lactate woman exclude , give potential teratogenic effect chemotherapy agent use transplant . Male female patient childbearing potential unwilling use effective mean contraception HIV HTLV I/II positive , hepatitis C chronic active hepatitis B . Patients previous malignancy unless deem treat physician low risk recurrence . Patient guardian unable give inform consent unable comply treatment protocol include appropriate supportive care , followup research test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>GVHD Prophylaxis</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>14-273</keyword>
</DOC>